Physician profile
Ashish Thakkar
NPI 1538456124
$1,055.47
in general payments reported to CMS, 2019-2025
24 companies · $31.05 in 2025
The $31.05 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $257 · 2020: $106 · 2021: $214 · 2022: $217 · 2023: $179 · 2024: $51.38 · 2025: $31.05.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $262.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $261.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $158.06 | 2019-2023 | Spiriva Respimat, Stiolto Respimat |
| Glaxosmithkline, LLC. | $157.24 | 2020-2023 | Trelegy Ellipta, Arexvy |
| United Therapeutics Corporation | $120.20 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $94.64 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $50.52 | 2019-2023 | |
| Insmed, INC. | $49.84 | 2020-2023 | Arikayce |
| Mallinckrodt Enterprises LLC | $48.60 | 2019 | |
| Abbvie INC. | $45.31 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $43.12 | 2021-2023 | Ultomiris |
| Grifols USA, LLC | $39.59 | 2020-2021 | |
| Mylan Specialty L.P. | $27.46 | 2019-2023 | Yupelri |
| Actelion Pharmaceuticals US, INC. | $22.57 | 2021 | |
| Janssen Pharmaceuticals, INC | $21.27 | 2024 | Xarelto |
| Vapotherm INC | $19.90 | 2022 | |
| Electromed, INC. | $19.89 | 2023 | Smartvest |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $17.90 | 2021 | |
| Merck Sharp & Dohme LLC | $17.12 | 2022 | |
| Verona Pharma, INC. | $15.85 | 2025 | Ohtuvayre |
| Allergan, INC. | $15.44 | 2019 | |
| Biogen, INC. | $15.30 | 2022 | |
| Mallinckrodt Hospital Products INC. | $15.29 | 2022 | |
| Ambu INC. | $14.13 | 2022 | |
| Circassia INC. | $13.33 | 2019 | |
| Pfizer INC. | $12.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashish Thakkar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.